BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15792800)

  • 1. Selection for TRAIL resistance results in melanoma cells with high proliferative potential.
    Wu JJ; Zhang XD; Gillespie S; Hersey P
    FEBS Lett; 2005 Mar; 579(9):1940-4. PubMed ID: 15792800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X; Li H
    Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel.
    Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
    Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
    Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
    Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.
    Secchiero P; Gonelli A; Carnevale E; Milani D; Pandolfi A; Zella D; Zauli G
    Circulation; 2003 May; 107(17):2250-6. PubMed ID: 12668516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amiloride potentiates TRAIL-induced tumor cell apoptosis by intracellular acidification-dependent Akt inactivation.
    Cho YL; Lee KS; Lee SJ; Namkoong S; Kim YM; Lee H; Ha KS; Han JA; Kwon YG; Kim YM
    Biochem Biophys Res Commun; 2005 Jan; 326(4):752-8. PubMed ID: 15607733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release.
    Gibson EM; Henson ES; Haney N; Villanueva J; Gibson SB
    Cancer Res; 2002 Jan; 62(2):488-96. PubMed ID: 11809700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
    Oka N; Nakahara S; Takenaka Y; Fukumori T; Hogan V; Kanayama HO; Yanagawa T; Raz A
    Cancer Res; 2005 Sep; 65(17):7546-53. PubMed ID: 16140916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL).
    Rychahou PG; Murillo CA; Evers BM
    Surgery; 2005 Aug; 138(2):391-7. PubMed ID: 16153452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis.
    Xiao C; Yang BF; Song JH; Schulman H; Li L; Hao C
    Exp Cell Res; 2005 Mar; 304(1):244-55. PubMed ID: 15707589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
    Liu X; Yue P; Khuri FR; Sun SY
    Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes.
    Larribere L; Khaled M; Tartare-Deckert S; Busca R; Luciano F; Bille K; Valony G; Eychene A; Auberger P; Ortonne JP; Ballotti R; Bertolotto C
    Cell Death Differ; 2004 Oct; 11(10):1084-91. PubMed ID: 15243584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents.
    Arizono Y; Yoshikawa H; Naganuma H; Hamada Y; Nakajima Y; Tasaka K
    Br J Cancer; 2003 Jan; 88(2):298-306. PubMed ID: 12610517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.